Related Experiment Video
Updated: Mar 7, 2026
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies
Solmaz Sahebjam1, Peter A Forsyth2, Keiran S Smalley3
1Department of Neuro-Oncology, Moffitt Cancer Center and Department of Oncologic, University of South Florida Morsani College of Medicine, Tampa, FL. Solmaz.Sahebjam@Moffitt.org.
Background:
Leptomeningeal metastasis is a consequence of advanced solid malignancies and has limited treatment options. It is possible that it is becoming more common as the leptomeninges act as a sanctuary site for recurrence from systemic cancer.
Methods:
Potential targeted and immunotherapy agents for the most common types of solid-tumor leptomeningeal metastasis are reviewed, as are their dosing/delivery strategies and novel, immunological approaches.
Results:
Historically, patients with leptomeningeal metastasis have been excluded from clinical trials, and data on the management of leptomeningeal metastasis come from single case reports and retrospective analyses.
Conclusion:
For the first time ever, published reports suggest the tide may be turning in this challenging disease.
